Pharmafile Logo
Pharmafocus logo
Advanced Search

Pancreatic cancer

Showing 15 posts of 26 posts found.

FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment

April 15, 2024
Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer

Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …

News

Arcus Biosciences shares results from phase 1b trial for pancreatic cancer treatment

January 18, 2024
Medical Communications Arcus Biosciences, Oncology, Pancreatic cancer, clinical trial

Arcus Biosciences has announced new data from the ARC-8 phase 1b clinical study which is being co-developed alongside Gilead Sciences. …

News

Jacobio Pharma receives CDE approval for pancreatic cancer study in China

July 5, 2023
Medical Communications CDE, China, Jacobio Pharma, Oncology, Pancreatic cancer, clinical trial

Jacobio Pharma has announced that its novel KRAS G12C inhibitor glecirasib’s pivotal study for pancreatic cancer has been approved by …

News

Servier and Aitia enter into R&D collaboration for pancreatic cancer using Digital Twins

May 18, 2023
Research and Development Aitia, Digital Twins, Oncology, Pancreatic cancer, Servier

French pharmaceutical company Servier and US-based Causal AI and Digital Twins company Aitia have announced a collaboration to create Digital …

News
lynparza

Lynparza secures CHMP recommendation in first-line BRCA-mutated metastatic pancreatic cancer

June 1, 2020
Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza

Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has just secured recommendation for approval from the European Medicines …

News
shutterstock_212432119

Opdivo + cabiralizumab combo falls flat in advanced pancreatic cancer

February 19, 2020
Research and Development Bristol-Myers Squibb, Five Prime Therapeutics, Pancreatic cancer, cabiralizumab, opdivo, pharma

Five Prime Therapeutics and Bristol-Myers Squibb have confirmed that their randomised Phase 2 trial investigating the efficacy of the former’s …

News
5204602349_c87b204860_b

FDA advisory committee approves the use of Lynparza in pancreatic cancer

December 18, 2019
Research and Development AstraZeneca, Cancer, Merck, Pancreatic cancer, lynparza

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca and Merck’s Lynparza (olaparib) to treat pancreatic …

News

Lilly’s pegilodecakin combo falls at Phase 3 in pancreatic cancer

October 17, 2019
Research and Development Cancer, Eli Lilly, FOLFOX, Pancreatic cancer, pegilodecakin, pharma

In disappointing news, Eli Lilly has revealed that pegilodecakin, in combination with the chemotherapy regimen FOLFOX (Folinic acid, Fluorouracil and …

News
shutterstock_159488225

Clovis Oncology’s Rubraca shows promise in multiple pancreatic tumour mutations, interim data show

April 3, 2019
Research and Development Cancer, Clovis Oncology, Pancreatic cancer, Rubraca, oncology, pharma

At the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Clovis Oncology took the opportunity to present …

News
lynparza

Lynparza extends progression-free survival in gBRCAm metastatic pancreatic cancer

February 26, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza, pharma

AstraZeneca and MSD have lifted the curtain on new Phase 3 data for Lynparza (olaparib), confirming that the drug generated …

News
celgene_1_02

NICE greenlights Celgene pancreatic cancer drug as first-line combination treatment

August 4, 2017
Medical Communications, Sales and Marketing Cancer, Celgene, NICE, Pancreatic cancer, drugs, healthcare, life sciences, medicine, pharma, pharmaceuticals

Celgene is celebrating following NICE’s announcement that it had decided to recommend the use of nab-Paclitaxel, when used in combination …

News
shutterstock_141299494

UK underperforming in cancer care compared to Europe, according to ABPI report

July 18, 2017
Research and Development ABPI, Cancer, Pancreatic cancer, biotech, heralthcare, lung cancer, ovarian cancer, pharma, pharmaceutical

According to a new report commissioned by the ABPI, the UK is continuing to fall behind in the diagnosis and …

News
shire_image_4

NICE turns down Shire’s pancreatic cancer treatment

April 4, 2017
Manufacturing and Production, Sales and Marketing NICE, Pancreatic cancer, Shire

NICE has announced its intention not to recommend the NHS use of Shire’s Onivyde (pegylated liposomal irinotecan) for the treatment …

News
shutterstock_204190579

Cancer Research UK announces £10m pancreatic cancer project

March 24, 2017
Medical Communications, Research and Development Cancer Research UK, Pancreatic cancer

Cancer Research UK has revealed a £10 million investment into PRECISION-Panc, a pancreatic cancer-focused project which aims to improve patient …

News
cancer_cells

Breakthrough treatment for pancreatic cancer doubles survival rates

January 25, 2017
Research and Development CRUK, Cancer Research UK, Pancreatic cancer

Research led by Liverpool University and funded by Cancer Research UK has shown that a combination treatment of two off-patent …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024